Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: A meta-analysis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Wenying ^a,b   Wang, Meilin ^b   Wang, Li ^b   Adams, Tamara S ^b   Tian, Ye ^a   Xu, Jianfeng ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD; CANCER GRADING; CASE CONTROL STUDY; HUMAN; MALE; META ANALYSIS; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX;

CASE-CONTROL STUDIES; HUMANS; MALE; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 84901400634     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05012     Document Type: Article

References (38)

1. Sokoll, L. J. et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology 61, 274-6 (2003).
2. Schroder, F. H. & Roobol, M. J. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol 19, 227-31 (2009).
3. Hori, S., Blanchet, J. S. & McLoughlin, J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms:a review ofthe emerging role of proPSAsinthe detection and management of early prostate cancer. BJU Int 112, 717-28 (2013).
4. Khan, M. A. et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 170, 723-6 (2003).
5. Stephan, C. et al. Multicenter evaluation of [22]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59, 306-14 (2013).
6. Lazzeri, M. et al. Serum index test %[22]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 188, 1137-43 (2012).
7. Jansen, F. H. et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57, 921-7 (2010).
8. Lazzeri, M. et al. Clinical performance of serum prostate-specific antigen isoform [22]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112, 313-21 (2013).
9. Lazzeri, M. et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [22]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 83, 606-12 (2014).
10. Guazzoni, G. et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60, 214-22 (2011).
11. Catalona, W. J. et al. A multicenter study of [22]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185, 1650-5 (2011).
12. Guazzoni, G. et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 61, 455-66 (2012).
13. Stephan, C. et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 59, 280-8 (2013).
14. Ferro, M. et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 413, 1274-8 (2012).
15. Mikolajczyk, S. D. et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50, 1017-25 (2004).
16. Loeb, S. et al. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol 189, 1702-6 (2013).
17. Lughezzani, G. et al. Multicenter European External Validation of a Prostate Health Index-based Nomogram for Predicting Prostate Cancer at Extended Biopsy. Eur Urol (2013).
18. Fossati, N. et al. Clinical performanceofserum isoform [22]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study. BJU Int (2014).
19. Lughezzani, G. et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 188, 1144-50 (2012).
20. Scattoni, V. et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 190, 496-501 (2013).
21. Perdona, S. et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73, 227-35 (2013).
22. Ferro, M. et al. Prostate Health Index (Phi) and Prostate Cancer Antigen3(PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One 8, e67687 (2013).
23. Lazzeri, M. et al. Serum isoform [22]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol 63, 986-94 (2013).
24. Ito, K. et al. Diagnostic significance of [22]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol 31, 305-11 (2013).
25. Le, B. V. et al. [22]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 183, 1355-9 (2010).
26. Sokoll, L. J. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [22]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19, 1193-200 (2010).
27. Stephan, C. et al. A [22]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69, 198-207 (2009).
28. Sokoll, L. J. et al. [22]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180, 539-43; discussion 543 (2008).
29. Catalona, W. J. et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170, 2181-5 (2003).
30. Ng, C. F. et al. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol (2013).
31. van Leeuwen, P. J. et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46, 377-83 (2010).
32. Mikolajczyk, S. D., Marks, L. S., Partin, A. W. & Rittenhouse, H. G. Free prostate-specific antigenin serum is becoming more complex. Urology 59, 797-802 (2002).
33. Filella, X. & Gimenez, N. Evaluation of [22] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 51, 729-39 (2013).
34. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009).
35. Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M. & Kleijnen, J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3, 25 (2003).
36. Whiting, P. et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 8, 1-234 (2004).
37. Deeks, J. J., Macaskill, P. & Irwig, L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58, 882-93 (2005).
38. Zamora, J., Abraira, V., Muriel, A., Khan, K. & Coomarasamy, A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6, 31 (2006).